PL1708790T3 - Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych - Google Patents

Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych

Info

Publication number
PL1708790T3
PL1708790T3 PL04801138T PL04801138T PL1708790T3 PL 1708790 T3 PL1708790 T3 PL 1708790T3 PL 04801138 T PL04801138 T PL 04801138T PL 04801138 T PL04801138 T PL 04801138T PL 1708790 T3 PL1708790 T3 PL 1708790T3
Authority
PL
Poland
Prior art keywords
antagonist
dopamin
pipamperone
serotonin
treatment
Prior art date
Application number
PL04801138T
Other languages
English (en)
Inventor
Erik Buntinx
Original Assignee
Pharmaneuroboost N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/725,965 external-priority patent/US7884096B2/en
Priority claimed from CA2451798A external-priority patent/CA2451798C/en
Priority claimed from EP03447279A external-priority patent/EP1547650A1/en
Priority claimed from US10/752,423 external-priority patent/US7855195B2/en
Priority claimed from EP04447066A external-priority patent/EP1576985A1/en
Priority claimed from CA 2461248 external-priority patent/CA2461248C/en
Priority claimed from US10/803,793 external-priority patent/US20050119249A1/en
Priority claimed from EP04025035A external-priority patent/EP1541197B8/en
Priority claimed from US10/984,683 external-priority patent/US20050203130A1/en
Priority claimed from CA 2487529 external-priority patent/CA2487529A1/en
Application filed by Pharmaneuroboost N V filed Critical Pharmaneuroboost N V
Publication of PL1708790T3 publication Critical patent/PL1708790T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL04801138T 2003-12-02 2004-12-02 Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych PL1708790T3 (pl)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US10/725,965 US7884096B2 (en) 2003-12-02 2003-12-02 Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2451798A CA2451798C (en) 2003-12-02 2003-12-02 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
EP03447279A EP1547650A1 (en) 2003-12-02 2003-12-02 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP04447001 2004-01-05
US10/752,423 US7855195B2 (en) 2003-12-02 2004-01-06 Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP04447066A EP1576985A1 (en) 2004-03-18 2004-03-18 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA 2461248 CA2461248C (en) 2003-12-02 2004-03-18 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US10/803,793 US20050119249A1 (en) 2003-12-02 2004-03-18 Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP04025035A EP1541197B8 (en) 2003-12-02 2004-10-21 Use of pipamperone and an SNDRI, SNRI or SSRI for the treatment of mood or anxiety disorders
JP2004349085A JP4571485B2 (ja) 2003-12-02 2004-11-04 Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用
US10/984,683 US20050203130A1 (en) 2003-12-02 2004-11-09 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA 2487529 CA2487529A1 (en) 2003-12-02 2004-11-15 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
PCT/BE2004/000172 WO2005053796A1 (en) 2003-12-02 2004-12-02 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
EP04801138A EP1708790B1 (en) 2003-12-02 2004-12-02 Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders

Publications (1)

Publication Number Publication Date
PL1708790T3 true PL1708790T3 (pl) 2010-10-29

Family

ID=34658360

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04801138T PL1708790T3 (pl) 2003-12-02 2004-12-02 Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych

Country Status (5)

Country Link
US (3) US8304431B2 (pl)
EP (2) EP1708790B1 (pl)
CA (1) CA2547639A1 (pl)
PL (1) PL1708790T3 (pl)
WO (1) WO2005053796A1 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004016288D1 (de) 2003-01-16 2008-10-16 Acadia Pharm Inc Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050119249A1 (en) * 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1708790B1 (en) * 2003-12-02 2010-04-21 PharmaNeuroBoost N.V. Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
GB0417702D0 (en) * 2004-08-09 2004-09-08 Merck Sharp & Dohme New uses
AU2006264317B2 (en) * 2005-07-06 2012-02-23 Sunovion Pharmaceuticals Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
EP2134330B1 (en) 2007-03-19 2013-05-08 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
WO2010026154A1 (en) 2008-09-04 2010-03-11 Neurosearch A/S A method for combating adverse effects arising from antipsychotic treatment
US8198268B2 (en) * 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
EP2413935A1 (en) 2009-03-30 2012-02-08 PharmaNeuroBoost N.V. Low dose pipamperone in treating mood disorders
EP2236157A1 (en) 2009-03-30 2010-10-06 PharmaNeuroBoost N.V. Pipamperone and a second agent in treating mood and anxiety disorders
EP2236138A1 (en) 2009-03-30 2010-10-06 PharmaNeuroBoost N.V. Low dose pipamperone in treating mood and anxiety disorders
RU2556585C2 (ru) 2009-11-06 2015-07-10 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома дефицита внимания и гиперактивности
WO2012072665A1 (en) 2010-11-30 2012-06-07 Pharmaneuroboost N.V. Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
WO2017015272A1 (en) 2015-07-20 2017-01-26 Acadia Pharmaceuticals Inc. Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗***股份公司 包含阿塞那平的透皮治疗***
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
EP3615028A1 (en) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
EP3720434A4 (en) 2017-12-05 2021-09-01 Sunovion Pharmaceuticals Inc. NON-RACEMIC MIXTURES AND THEIR USE
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗***股份公司 含有阿塞那平的透皮治疗***
US20210393595A1 (en) * 2018-09-25 2021-12-23 Chase Therapeutics Corporation Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
KR20220052927A (ko) * 2019-07-19 2022-04-28 스프루스 바이오사이언시스 인코포레이티드 선천성 부신 증식증의 치료 방법

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4797419A (en) 1986-11-03 1989-01-10 Warner-Lambert Company Method of treating the symptoms of senile cognitive decline employing di- or trisubstituted urea cholinergic agents
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5759837A (en) 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
DE4039631A1 (de) * 1990-12-12 1992-06-17 Troponwerke Gmbh & Co Kg Neuroprotektive kombination
DE4138756A1 (de) 1991-11-26 1993-05-27 Troponwerke Gmbh & Co Kg Kombination mit neuroprotektiver wirkung
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
FR2749304B1 (fr) 1996-06-04 1998-06-26 Adir Nouveaux derives du 3-(piperid-4-yl)1,2-benzisoxazole et du 3-(piperazin-4-yl)1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
ZA982368B (en) 1997-03-27 1998-09-23 Akzo Nobel Nv New therapeutic combinations
GB9718833D0 (en) 1997-09-04 1997-11-12 Merck Sharp & Dohme Therapeutic agents
US5955459A (en) 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
GB2336534A (en) 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
DE19836406A1 (de) 1998-08-12 2000-02-17 Basf Ag N-Substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung
US6358698B1 (en) 1998-10-07 2002-03-19 Acadia Pharmacueticals Inc. Methods of identifying inverse agonists of the serotonin 2A receptor
WO2000064441A2 (en) 1999-04-28 2000-11-02 Respiratorius Ab Compound for use as a medicament for treatment of disorders involving bronchocontraction
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US20050148018A1 (en) 1999-10-07 2005-07-07 David Weiner Methods of identifying inverse agonists of the serotonin 2A receptor
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
AR028945A1 (es) 2000-06-19 2003-05-28 Lundbeck & Co As H Derivados de indol
US20040002482A1 (en) 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
AR035521A1 (es) 2000-12-22 2004-06-02 Lundbeck & Co As H Derivados de 3-indolina y composicion farmaceutica que los comprende
DE602004016288D1 (de) 2003-01-16 2008-10-16 Acadia Pharm Inc Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen
EP1615924A1 (en) 2003-04-22 2006-01-18 Synthon B.V. Water soluble salts of risperidone
CA2461248C (en) 2003-12-02 2009-12-22 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US20050119249A1 (en) 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1708790B1 (en) 2003-12-02 2010-04-21 PharmaNeuroBoost N.V. Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
US20050203130A1 (en) 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
EP2413935A1 (en) 2009-03-30 2012-02-08 PharmaNeuroBoost N.V. Low dose pipamperone in treating mood disorders

Also Published As

Publication number Publication date
CA2547639A1 (en) 2005-06-16
EP2272514A1 (en) 2011-01-12
US8304431B2 (en) 2012-11-06
US20110136865A1 (en) 2011-06-09
US20070078162A1 (en) 2007-04-05
EP1708790A1 (en) 2006-10-11
US20110207776A1 (en) 2011-08-25
WO2005053796A1 (en) 2005-06-16
EP1708790B1 (en) 2010-04-21

Similar Documents

Publication Publication Date Title
PL1708790T3 (pl) Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych
AU2003249983A8 (en) Piperidines useful for the treatment of central nervous system disorders
HK1079203A1 (en) Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders
IL176248A0 (en) N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
IL166058A0 (en) Novel thiophenylglycoside derivatives methods for production thereof medicaments comprising said compounds and use thereof
GB0215853D0 (en) Summarisation representation apparatus
IL163158A (en) 4-(4-methyl- piperazin -1- ylmethyl)- benzamide derivatives
HUP0302719A3 (en) Substituted amine derivatives and their use for the treatment of angiogenesis
IL169336A0 (en) Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
IL157328A0 (en) Treatment involving dkk-1 or antagonists thereof
EP1527196A4 (en) TREATMENT OF ASTHMA OR ALLERGIES
SI1487828T1 (sl) Morfolinil-sečninski derivati za uporabo pri zdravljenu vnetnih bolezni
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
AU2003275056A8 (en) Novel lapacho compounds and methods of use thereof
AU2003210730A8 (en) Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
HUP0301551A3 (en) New use of 5ht3 and neuronal nicotinicreceptor antagonist 1-amino-alkycyclohexanes
NO20043354L (no) Terapeutiske akridon- og akridinforbindelser
IL158703A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL169337A0 (en) Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
GB0207410D0 (en) Compounds and their therapeutic use
EP1558238A4 (en) BETA-HYDROXYPHENYL ALDYLAMINE AND ITS USE FOR THE TREATMENT OF GLAUCOMA
IL158632A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
SI1708790T1 (sl) Uporaba pipamerona in d receptorskega antagonista kot serotonin dopamin antagonista za zdravljenjepsihičnih nepravilnosti
PT1503746E (pt) Utilização farmacêutica de inibidores da cox-2 em perturbações oculares mediadas pela angiogénese